Syngene International Share Price

Syngene International Limited is one of India’s largest comprehensive medical services providers. The company offers integrated services in the areas of research, development and manufacturing, for delivering scientific solutions to advance human and animal health, speciality chemicals, and consumer goods industries.

The company has been an industry leader for over 3 decades. The company has over 6,000 scientists working for it. The company owns over 400 patents under its name.

Syngene International Limited was initially incorporated as “Syngene International Private Limited” in November 1993. The company was later converted into a public listed company in March 2007 and renamed “Syngene International Limited”.

Syngene International Limited is listed on both the National Stock Exchange and BSE. The company was listed on the stock exchanges in 2015.

Syngene International Limited is a mid-cap company with a market capitalisation of nearly ₹30,000 crore as of February 17, 2024. Syngene International share price has surged over 28% in the last 3 years.

Business and Operation

Syngene International Limited is headquartered in Bengaluru, where its main campus serves as the primary research, development, and manufacturing hub. The company operates three satellite campuses in Bengaluru. These centres house human resources, legal, finance, and our clinical development operations. The company has set up two more campuses in Hyderabad and Mangalore. In Hyderabad, its expanding discovery research operations are situated within the government-sponsored biotech zone, while in Mangalore, a dedicated campus accommodates commercial-scale active pharmaceutical ingredient (API) manufacturing units.

Syngene USA Inc. is Syngene International Limited’s US-based wholly-owned subsidiary supporting clients in the United States. The clients in the United Kingdom and Europe are served by its locally-based commercial teams. Syngene International Limited has various partnerships with large and mid-sized biopharma companies, emerging biopharma (EPB) companies, animal health companies, agrochem companies, consumer products companies and chemicals/polymers companies.

Syngene International Limited has a discovery services division. It plays a critical role in driving early-stage research initiatives. It identifies relevant biological targets in patient populations and delivers potential drug candidates for further development. The expertise of this division contains various disciplines including chemistry, biology, safety assessment and data sciences. It addresses various therapeutic modalities such as traditional small molecule therapeutics, biologics, peptides, oligonucleotides, antibody-drug conjugates and targeted degradation/stabilisation. Syngene SynVent is the company’s integrated drug discovery platform. It offers comprehensive project delivery capabilities to clients. It utilises advanced technologies and scientific expertise to efficiently progress drug discovery.

Syngene Internal Limited has a development services division. It offers a comprehensive range of services for drug candidates, spanning from pre-clinical to clinical trials. The services include drug substance and drug product development. Additionally, it has services aimed at demonstrating the safety, tolerability, and efficacy of drugs. The company offers highly potent active pharmaceutical ingredients and oligonucleotides that have therapeutic and diagnostic applications, ranging from laboratory to manufacturing scale. The company specialises in performance chemicals and speciality materials using synthetic organic chemistry and polymer chemistry.

Financial highlights

• The company’s consolidated revenue increased to ₹3,263.8 crore in FY23, up 23% compared to ₹2,657 crore in FY22.
• Its EBITDA (earnings before interest, taxes, depreciation, and amortisation) stood at ₹934.4 crore in FY23.
• The company’s EBITDA margin stood at 29.3% in FY23 as against 30.6% in FY22.
• Its profit after tax (PAT) advanced by 17.33% year-on-year to ₹464.4 crore in FY23, compared to ₹395.8 crore in FY22.
• Its earnings per share (EPS) stood at ₹11.59 in FY23 as against ₹9.94 in FY22.